Published in AIDS Weekly, March 10th, 1997
Treatment with interleukin 2 (IL-2) apparently jump-starts this stalled process, according to R.A. Lempicki, H. Clifford Lane, and colleagues at the National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland.
"Administration of IL-2, in vivo or in vitro, may prevent cell cycle arrest and induce CD8+ T cells to progress normally through the cell cycle and to engage in proper effector function," Lempicki et al. wrote in the abstract of their presentation to the Fourth Conference on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.